
-
IDEAYA Biosciences NasdaqGS:IDYA IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Location: 5000 Shoreline Court, South San Francisco, CA, 94080, United States | Website: https://www.ideayabio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.089B
Cash
692.5M
Avg Qtr Burn
-66.03M
Short % of Float
12.31%
Insider Ownership
0.91%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Darovasertib Details Uveal melanoma | Phase 3 Initiation | |
Darovasertib (IDE196) + crizotinib Details Solid tumor/s, Metastatic uveal melanoma, Cancer | Phase 2/3 Data readout | |
Darovasertib Details Cancer, Ocular melanoma | Phase 2 Data readout | |
Darovasertib (IDE196) + crizotinib Details Solid tumor/s, Metastatic uveal melanoma, Cancer, Cutaneous Melanoma | Phase 2 Data readout | |
IDE397 (MAT2A) Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Bladder cancer | Phase 1/2 Data readout | |
GSK101 (IDE705) + niraparib Details Cancer, Solid tumor/s | Phase 1/2 Update | |
IDE849 (SHR-4849) Details Solid tumors | Phase 1 Data readout | |
IDE397 (MAT2A) + Trodelvy Details MTAP-Deletion Urothelial Cancer | Phase 1 Data readout | |
IDE161 +/- KEYTRUDA® (pembrolizumab) Details Solid tumor/s, Cancer, ER+/HER2- breast cancer, Ovarian cancer, Endometrial cancer | Phase 1 Update | |
IDE275 (GSK959) Details Solid tumor/s, Cancer | Phase 1 Initiation | |
IDE397 (MAT2A) +/- AMG 193 Details Solid tumor/s, Cancer, Non-small cell lung carcinoma | Failed Discontinued |